E. Ohman J or Asset Management AB Has $480,000 Position in Charles River Laboratories International, Inc. (NYSE:CRL)

E. Ohman J or Asset Management AB boosted its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 225.0% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 2,600 shares of the medical research company's stock after buying an additional 1,800 shares during the quarter. E. Ohman J or Asset Management AB's holdings in Charles River Laboratories International were worth $480,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of CRL. Cetera Investment Advisers boosted its holdings in Charles River Laboratories International by 2.4% in the second quarter. Cetera Investment Advisers now owns 9,969 shares of the medical research company's stock valued at $2,059,000 after acquiring an additional 229 shares during the last quarter. Handelsbanken Fonder AB lifted its position in Charles River Laboratories International by 18.4% during the 3rd quarter. Handelsbanken Fonder AB now owns 12,237 shares of the medical research company's stock valued at $2,410,000 after purchasing an additional 1,900 shares during the period. Czech National Bank boosted its stake in shares of Charles River Laboratories International by 7.1% in the 3rd quarter. Czech National Bank now owns 10,517 shares of the medical research company's stock valued at $2,072,000 after purchasing an additional 701 shares during the last quarter. GAMMA Investing LLC grew its position in shares of Charles River Laboratories International by 22.6% during the 3rd quarter. GAMMA Investing LLC now owns 1,041 shares of the medical research company's stock worth $205,000 after buying an additional 192 shares during the period. Finally, Fulton Bank N.A. lifted its holdings in Charles River Laboratories International by 2.8% in the third quarter. Fulton Bank N.A. now owns 3,396 shares of the medical research company's stock valued at $669,000 after buying an additional 91 shares during the period. 98.91% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

CRL has been the subject of a number of analyst reports. JPMorgan Chase & Co. lowered their target price on shares of Charles River Laboratories International from $215.00 to $175.00 and set a "neutral" rating for the company in a report on Monday, February 3rd. TD Cowen upped their price objective on Charles River Laboratories International from $203.00 to $227.00 and gave the company a "hold" rating in a report on Monday, November 11th. Redburn Atlantic began coverage on Charles River Laboratories International in a report on Monday, October 14th. They set a "sell" rating and a $151.00 target price on the stock. CLSA cut Charles River Laboratories International from a "hold" rating to an "underperform" rating and set a $164.00 price target for the company. in a research note on Monday, November 18th. Finally, UBS Group reiterated a "neutral" rating and issued a $185.00 price target (down from $250.00) on shares of Charles River Laboratories International in a research report on Friday, January 17th. Three investment analysts have rated the stock with a sell rating, fourteen have issued a hold rating and one has given a buy rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and an average price target of $200.79.

Charles River Laboratories International Stock Down 1.6 %

NYSE CRL traded down $2.62 on Friday, reaching $163.65. The company had a trading volume of 564,421 shares, compared to its average volume of 1,002,698. The company's fifty day moving average is $180.61 and its 200-day moving average is $193.44. The firm has a market capitalization of $8.37 billion, a price-to-earnings ratio of 20.48, a price-to-earnings-growth ratio of 6.47 and a beta of 1.37. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.14 and a current ratio of 1.48. Charles River Laboratories International, Inc. has a 1-year low of $159.65 and a 1-year high of $275.00.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last posted its quarterly earnings data on Wednesday, November 6th. The medical research company reported $2.59 earnings per share for the quarter, topping the consensus estimate of $2.43 by $0.16. The company had revenue of $1.01 billion during the quarter, compared to analysts' expectations of $975.99 million. Charles River Laboratories International had a return on equity of 14.29% and a net margin of 10.44%. Charles River Laboratories International's revenue for the quarter was down 1.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.72 earnings per share. On average, research analysts forecast that Charles River Laboratories International, Inc. will post 10.16 earnings per share for the current fiscal year.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).